Clinically Established Biodegradable Long Acting Injectables: An Industry Perspective

Clinically Established Biodegradable Long Acting Injectables: An Industry Perspective Publisher Pubmed

Nkanga CI^{1, 2, 3} ; Fisch A³ ; Radmalekshahi M⁴ ; Romic MD³ ; Kittel B⁵ ; Ullrich T⁵ ; Wang J³ ; Krause RWM¹ ; Adler S³ ; Lammers T⁶ ; Hennink WE⁷ ; Ramazani F³

Show Affiliations

1. Center for Chemico- and Bio-Medicinal Research (CCBR), Department of Chemistry, Rhodes University, P.O. Box 94, Grahamstown, 6140, South Africa
2. Faculty of Pharmaceutical Sciences, University of Kinshasa, B.P. 212, Kinshasa, XI, Democratic Republic Congo
3. Technical Research and Development, Novartis Pharma AG, Basel, 4002, Switzerland
4. Department of Pharmaceutical Biomaterials and Medical Biomaterials Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
5. Novartis Institute for Biomedical Research, Novartis Pharma AG, Basel, 4002, Switzerland
6. Department of Experimental Molecular Imaging, RWTH Aachen University, Aachen, Germany
7. Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Netherlands

Source: Advanced Drug Delivery Reviews Published:2020

Abstract

Long acting injectable formulations have been developed to sustain the action of drugs in the body over desired periods of time. These delivery platforms have been utilized for both systemic and local drug delivery applications. This review gives an overview of long acting injectable systems that are currently in clinical use. These products are categorized in three different groups: biodegradable polymeric systems, including microparticles and implants; micro and nanocrystal suspensions and oil-based formulations. Furthermore, the applications of these drug delivery platforms for the management of various chronic diseases are summarized. Finally, this review addresses industrial challenges regarding the development of long acting injectable formulations. © 2020 Elsevier B.V.

Related Docs

View other Related Docs

1. Pharmaceutical Implants: Classification, Limitations and Therapeutic Applications, Pharmaceutical Development and Technology (2020)

2. Peptide Acylation in Aliphatic Polyesters: A Review of Mechanisms and Inhibition Strategies, Pharmaceutical Research (2024)

3. Biodegradable in Situ Forming and Preformed Implants, Biodegradable Long Acting Injectables and Implants: An Industry View (2025)

4. Design of Experiments Approach for the Development of a Validated Method to Determine the Exenatide Content in Poly(Lactide-Co-Glycolide) Microspheres, European Journal of Pharmaceutics and Biopharmaceutics (2023)

5. In-Vitro and In-Vivo Comparison of Rsag1-Loaded Plga Prepared by Encapsulation and Adsorption Methods As an Efficient Vaccine Against Toxoplasma Gondii”, Journal of Drug Delivery Science and Technology (2020)

6. Release of Human Growth Hormone From an In-Situ Implant Modulated by Poly(Ethylene Glycol) Dimethyl Ether and Tris(Hydroxymethyl) Aminomethane, Iranian Polymer Journal (English Edition) (2020)

7. Synergistic Effect of Rsag1 and Rgra2 Antigens Formulated in Plga Microspheres in Eliciting Immune Protection Against Toxoplasama Gondii, Experimental Parasitology (2016)

8. Acylation of Arginine in Goserelin-Loaded Plga Microspheres, European Journal of Pharmaceutics and Biopharmaceutics (2016)

Experts (# of related papers)

View all Related Experts

Rassoul Dinarvand (7)

Fatemeh Atyabi (3)

Style	Citing Format
MLA	Nkanga CI, et al.. "Clinically Established Biodegradable Long Acting Injectables: An Industry Perspective." Advanced Drug Delivery Reviews, vol. 167, no. , 2020, pp. 19-46.
APA	Nkanga CI, Fisch A, Radmalekshahi M, Romic MD, Kittel B, Ullrich T, Wang J, Krause RWM, Adler S, Lammers T, Hennink WE, Ramazani F (2020). Clinically Established Biodegradable Long Acting Injectables: An Industry Perspective. Advanced Drug Delivery Reviews, 167(), 19-46.
Chicago	Nkanga CI, Fisch A, Radmalekshahi M, Romic MD, Kittel B, Ullrich T, Wang J, et al.. "Clinically Established Biodegradable Long Acting Injectables: An Industry Perspective." Advanced Drug Delivery Reviews 167, no. (2020): 19-46.
Harvard	Nkanga CI et al. (2020) 'Clinically Established Biodegradable Long Acting Injectables: An Industry Perspective', Advanced Drug Delivery Reviews, 167(), pp. 19-46.
Vancouver	Nkanga CI, Fisch A, Radmalekshahi M, Romic MD, Kittel B, Ullrich T, et al.. Clinically Established Biodegradable Long Acting Injectables: An Industry Perspective. Advanced Drug Delivery Reviews. 2020;167():19-46.
BibTex	@article{ author = {Nkanga CI and Fisch A and Radmalekshahi M and Romic MD and Kittel B and Ullrich T and Wang J and Krause RWM and Adler S and Lammers T and Hennink WE and Ramazani F}, title = {Clinically Established Biodegradable Long Acting Injectables: An Industry Perspective}, journal = {Advanced Drug Delivery Reviews}, volume = {167}, number = {}, pages = {19-46}, year = {2020} }
RIS	TY - JOUR AU - Nkanga CI AU - Fisch A AU - Radmalekshahi M AU - Romic MD AU - Kittel B AU - Ullrich T AU - Wang J AU - Krause RWM AU - Adler S AU - Lammers T AU - Hennink WE AU - Ramazani F TI - Clinically Established Biodegradable Long Acting Injectables: An Industry Perspective JO - Advanced Drug Delivery Reviews VL - 167 IS - SP - 19 EP - 46 PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract